摘要:
The invention relates to biomarkers for typing or classifying allograft recipients as belonging to a transplant rejection group associated with antibody-mediated rejection (ABMR). The invention also provides for the treatment of typed allograft recipients suffering from antibody-mediated rejection by administration of an appropriate therapeutic agent.
摘要:
The inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to a method of treating a subject suffering from a cancer comprising a step of administration simultaneously, separately or sequentially to said subject a therapeutically amount of i) a population of derived engineered fetal stem cells carrying cancer associated fetal neo-antigen and ii) a compound selected from a group which activates immune response, as a combined preparation.
摘要:
L'invention concerne une chambre de culture et d'imagerie (10) comprenant un support (1) rigide et un couvercle (5), au moins une lamelle de microscope (2, 12) disposée face à une ouverture (11, 15) formée dans le support (1) ou dans le couvercle (5), un joint d'étanchéité(4, 14, 24) comprenant au moins une autre ouverture (34) disposée face à la lamelle de microscope (2, 12) et une couche d'hydrogel (6) disposée à l'intérieur de ladite autre ouverture (34) du joint d'étanchéité (4, 14, 24), la couche d'hydrogel (6) comprenant un réseau de puits, le réseau de puits comprenant une pluralité de puits (26) ouverts de dimensions millimétriques ou sub-millimétriques disposés à des positions prédéterminées en trois dimensions dans un repère orthonormé lié au support (1), chaque puits (26) étant adapté pour recevoir un échantillon biologique.
摘要:
La présente invention se rapporte au domaine de la cardiologie, et plus particulièrement à un nouvel algorithme utilisable notamment dans un procédé permettant de déterminer si un médicament est susceptible d'induire un trouble de la repolarisation ventriculaire cardiaque sur la base de variations de données d'électrocardiogramme.
摘要:
The present invention relates to methods for diagnosing and treating CD1d-restricted gamma/delta T cell lymphomas. In particular, the present invention relates to a method for diagnosing a T cell lymphoma as a CD1d-restricted gamma/delta T cell lymphoma in a patient in need thereof comprising i) detecting the presence of CD1d restricted gamma/delta T lymphoma cells in a cell lymphoma sample obtained from the patient and ii) concluding that the T cell lymphoma is a CD1d-restricted gamma/delta T cell lymphoma when the presence of CD Id restricted gamma/delta T cells is detected in the sample. The present invention also relates to a method for treating a CD1d-restricted gamma/delta T cell lymphoma as diagnosed by the diagnostic method of present invention comprising administering the patient with a therapeutically effective amount of a CD1d antagonist.
摘要:
The invention relates to in vitro methods for the detection of an autoimmune disease or of a high-risk pregnancy in a subject, or for the determination of the predisposition of a subject to develop an autoimmune disease, to develop a high-risk pregnancy or to experience an implantation failure, comprising the determination of the presence of and/or the measure of the quantity of anti-CD 146 auto-antibodies in a biological sample of the subject and comparison to a control value.
摘要:
The present invention concerns novel dibenzo[c,h] [1, 5]naphthyridine of formula (I) and their use as DNA probes, as well as the methods for marking DNA using the same .
摘要:
Hepatitis Bis a serious liver infection caused by the hepatitis B virus (HBV). Current therapeutic approaches to HBV infection have severe limitations. Antiviral medications, e.g., tenofovir, a nucleotide reverse transcriptase inhibitor, can decrease viral replication but do not cure HBV infected patients. Due to the extent of liver damage caused by HBV, a transplant becomes necessary in some cases. In addition to the risks inherent in organ transplants, the cost can be prohibitive. Therefore, improved methods for treating HBV infection are urgently required. The invention features compositions and methods for introducing mutations into the hepatitis B virus (HBV) genome.
摘要:
The present application relates to peptides derived from the transmembrane domain of Plexin-A1 that inhibits Neuropilin-1/Plexin-A1 heterodimerization. These peptides neutralize the inhibitory effect of Sema3A on cell migration and angiogenesis, and may be useful for the treatment of diseases associated with Sema3A and/or Neuropilin-1/Plexin-A1 activity, such as demyelinating diseases and diseases associated with abnormal angiogenesis such as cancer.
摘要:
The invention relates to the use of a JAK inhibitor for treating or preventing adverse events in patient treated with an immune checkpoint inhibitor, or for treating cancer in combination with an immune checkpoint inhibitor.